The effect of zinc supplementation on young women with premenstrual syndrome

The effect of zinc supplementation on psychological and physical symptoms, sleep quality, quality of life, total antioxidant capacity, serum concentrations of Brain derived neurotrophic factor and high-sensitivity C-reactive protein in young women with premenstrual syndrome

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180215038738N1

Enrollment

Registered

2018-05-29

Start date

2017-06-22

Completion date

Unknown

Last updated

2018-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

premenstrual syndrome. Premenstrual tension syndrome

Interventions

Intervention 1: Intervention group: Supplementation of zinc gluconate including 30 mg of elemental zinc (Dine Iran Pharmaceutical Company ),every day 1 supplement, 12 weeks. Intervention 2: Control g

Eligibility

Sex/Gender

Female

Age

18 Years to 30 Years

Inclusion criteria

Inclusion criteria: 18.5 < Body mass index (BMI) < 25 single women regular menstrual cycle of 21-35 days

Exclusion criteria

Exclusion criteria: taking any medications containing estrogen and progesterone taking zinc supplement in past 3 months exercising regularly being depressed or having anxiety

Design outcomes

Secondary

Measure	Time frame
Sleep quality. Timepoint: before and 12 weeks after the start of intervention. Method of measurement: pittsburgh sleep quality index.;Quality of life. Timepoint: before and 12 weeks after the start of intervention. Method of measurement: World Health Organization Quality Of Life questionnaire.	—

Primary

Measure	Time frame
Physical symptoms of young women with premenstrual syndrome. Timepoint: before and 12 weeks after the start of intervention. Method of measurement: daily record questionnaire.;Psychological symptoms of young women with premenstrual syndrome. Timepoint: before and 12 weeks after the start of intervention. Method of measurement: daily record questionnaire.;Total antioxidant capacity. Timepoint: before and 12 weeks after the start of intervention. Method of measurement: Laboratory analysis ( blood test).;Serum concentrations of Brain derived neurotrophic factor. Timepoint: before and 12 weeks after the start of intervention. Method of measurement: Laboratory analysis ( blood test).;Serum concentrations of high-sensitivity C-reactive protein. Timepoint: before and 12 weeks after the start of intervention. Method of measurement: Laboratory analysis ( blood test).;Serum concentrations of zinc. Timepoint: before and 12 weeks after the start of intervention. Method of measurement: Laboratory analysis ( blood test).	—

Measure

Time frame

Physical symptoms of young women with premenstrual syndrome. Timepoint: before and 12 weeks after the start of intervention. Method of measurement: daily record questionnaire.;Psychological symptoms of young women with premenstrual syndrome. Timepoint: before and 12 weeks after the start of intervention. Method of measurement: daily record questionnaire.;Total antioxidant capacity. Timepoint: before and 12 weeks after the start of intervention. Method of measurement: Laboratory analysis ( blood test).;Serum concentrations of Brain derived neurotrophic factor. Timepoint: before and 12 weeks after the start of intervention. Method of measurement: Laboratory analysis ( blood test).;Serum concentrations of high-sensitivity C-reactive protein. Timepoint: before and 12 weeks after the start of intervention. Method of measurement: Laboratory analysis ( blood test).;Serum concentrations of zinc. Timepoint: before and 12 weeks after the start of intervention. Method of measurement: Laboratory analysis ( blood test).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatemeh Jafari

Esfahan University of Medical Sciences

f.jafari.nut@gmail.com+98 71 3234 4866

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026